Richard Bleicher named chief of new Division of Breast Surgery at Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Richard Bleicher

Richard Bleicher, a professor in the Department of Surgical Oncology and clinical director of the Breast Service Line, has been promoted to chief of the new Division of Breast Surgery at Fox Chase Cancer Center. 

The newly formed Division of Breast Surgery was created to focus efforts at Fox Chase on increasing access for breast cancer patients, as well as on clinical trials and research. In his new role, Bleicher will oversee the division’s programs, research portfolio, and all clinical activities. Additionally, he will provide support for the recruitment of new faculty and the growth of the breast program at all Fox Chase satellite campuses, as well as lead and manage the division. 

Bleicher has been instrumental in expanding the breast faculty within the department and growing the breast surgical program in volume, location, and scope. He will continue to serve as the clinical director of the Breast Service Line at Fox Chase, a position he has held since June 2023. 

Bleicher specializes in breast cancer with a focus on novel treatment modalities, clinical trials, and cosmetic outcomes, but he is most highly recognized and cited for his research regarding the impact of timeliness and delays on breast cancer treatment. His work is the basis for two current Commission on Cancer national quality measures. 

He frequently deals with cases that are not commonly seen by other clinicians, including unusual pathology results, complex cases, and rare clinical situations such as male breast cancer. His research interests include health services research, breast imaging, population studies, sentinel node biopsy in breast cancer, and disparities in breast cancer, among others. 

Table of Contents

YOU MAY BE INTERESTED IN

The Menarini Group and Stemline Therapeutics will present new and expanded data on Orserdu at the upcoming 2024 San Antonio Breast Cancer Symposium, held from Dec. 10-13. The company will bring real-world progression-free survival results of Orserdu in adult patients with ER+/HER2-, advanced or metastatic breast cancer. Additionally, the company will present updated efficacy results of elacestrant plus abemaciclib, along with a pooled safety analysis from phase Ib/2 of both the ELECTRA and ELEVATE trials.
Breast, bladder, and pancreatic cancers are increasingly being treated with a broad range of therapies before a patient undergoes surgery, and cancer stage at diagnosis continues to be a leading factor in determining a person’s survival rate for all types of cancer, according to the first-ever annual cancer report from the National Cancer Database.
FDA recently approved Alternative Standard #25 related to the Mammography Quality Standards Act. Alternative Standard #25 allows the interpreting physician to provide an assessment of “Incomplete: Need additional imaging evaluation” for the follow-up report issued within 30 calendar days of an initial report that received an assessment of “Incomplete: Need prior mammograms for comparison.”

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login